Senescence-accelerated OXYS rats: A model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Senescence-accelerated OXYS rats are an experimental model of accelerated aging that was established from Wistar stock via selection for susceptibility to cataractogenic effects of a galactose-rich diet and via subsequent inbreeding of highly susceptible rats. Currently, we have the 102nd generation of OXYS rats with spontaneously developing cataract and accelerated senescence syndrome, which means early development of a phenotype similar to human geriatric disorders, including accelerated brain aging. In recent years, our group found strong evidence that OXYS rats are a promising model for studies of the mechanisms of brain aging and neurodegenerative processes similar to those seen in Alzheimer disease (AD). The manifestation of behavioral alterations and learning and memory deficits develop since the fourth week of age, i.e., simultaneously with first signs of neurodegeneration detectable on magnetic resonance imaging and under a light microscope. In addition, impaired long-term potentiation has been demonstrated in OXYS rats by the age of 3 months. With age, neurodegenerative changes in the brain of OXYS rats become amplified. We have shown that this deterioration happens against the background of overproduction of amyloid precursor protein (AβPP), accumulation of β-amyloid (Aβ), and hyperphosphorylation of the tau protein in the hippocampus and cortex. The development of AMD-like retinopathy in OXYS rats is also accompanied by increased accumulation of Aβ in the retina. These published data suggest that the OXYS strain may serve as a spontaneous rat model of AD-like pathology and could help to decipher the pathogenesis of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“The pathological accumulation of Aβ, the canonical dysfunction of AD, is associated with an imbalance between its production and clearance as a result of diseasecausing changes in the processing of AβPP in the brain.(89) AβPP is a transmembrane protein expressed in the adult brain, where it participates in synaptogene…”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Disruption of Large-Scale Brain Systems in Advanced Aging
Andrews-Hanna, J. R., Snyder, A. Z., Vincent, J. L., Lustig, C., Head, D., Raichle, M. E., & Buckner, R. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.10.038 · Cited by 1,592
Adult hippocampal neurogenesis and its role in Alzheimer’s disease
Mu, Y., & Gage, F. H. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-85 · Cited by 1,021
Increased hippocampal neurogenesis in Alzheimer's disease
Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., & Greenberg, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2634794100 · Cited by 971
Gruver, A., Hudson, L., & Sempowski, G. (2007) · The Journal of Pathology · doi:10.1002/path.2104 · Cited by 834 · cited 1×
“Progressive involution of the thymus, a hallmark of aging, leads to a decline of those immune functions that are related to T cell-dependent immunity.(108,109) Because immunosenescence is progressive and generalized deterioration of immune functions that affects all cells and organs of the innate and adaptive immunity…”
BackgroundTau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 1×
“In contrast, there is growing evidence that mitochondrial damage and oxidative stress lead to activation of the Aβ cascade.(3,6,7) In regard to inflammatory cells, microglia can form a protective network for the brain to control neurotrophic factors, limit oxidative stress, and foster neuronal regeneration.”
BackgroundA learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Streit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562 · cited 1×
“In contrast, there is growing evidence that mitochondrial damage and oxidative stress lead to activation of the Aβ cascade.(3,6,7) In regard to inflammatory cells, microglia can form a protective network for the brain to control neurotrophic factors, limit oxidative stress, and foster neuronal regeneration.”
BackgroundA selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients
Maurer, I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00112-3 · Cited by 475
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432
Reddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V., Shirendeb, U. P., Calkins, M. J., Reddy, A. P., Mao, P., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.011 · Cited by 394 · cited 16×
“Critical for learning and memory, the hippocampus is one of the first brain regions to be affected by AD.53 The analysis of the neuronal populations CA1 and CA3 (Fig.”
BackgroundInfluentialParallel findings in age-related macular degeneration and Alzheimer’s disease
Ohno-Matsui, K. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.02.004 · Cited by 280
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
Age-related macular degeneration (AMD): Alzheimer's disease in the eye?
Kaarniranta, K., Salminen, A., Haapasalo, A., Soininen, H., & Hiltunen, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101908 · Cited by 248
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223 · cited 2×
“At present, it is widely debated whether AMD shares some pathological hallmarks with AD, because a number of similarities between AD and AMD have been described.15-18 Like AD, AMD is characterized by Aβ deposition and is associated with changes in the complement system and ApoE.19,20 To date, there is no perfect roden…”
BackgroundStreit, W. J., & Xue, Q.-S. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9163-5 · Cited by 205
Xiao, Q., Gil, S.-C., Yan, P., Wang, Y., Han, S., Gonzales, E., Perez, R., Cirrito, J. R., & Lee, J.-M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338376 · Cited by 194 · cited 1×
“Recent genome-wide association studies (GWAS) have found that PICALM mutations are significantly associated with AD, suggesting that PICALM has a hand in AβPP endocytosis and Aβ generation.(101,102) APBA2 is a neuronal adaptor protein that interacts directly with AβPP and stabilizes it, thereby inhibiting the producti…”
BackgroundKobayashi, M., Takeda, M., Sato, T., Yamazaki, Y., Kaneko, K., Ito, K.-I., Kato, H., & Inaba, H. (1999) · Neuroscience Research · doi:10.1016/s0168-0102(99)00040-1 · Cited by 180 · cited 1×
“It is now evident, however, that the concept has been oversimplified, and that the intensity of ROS generation in various brain regions strongly depends on energy metabolism and electrophysiological activity of the brain.(79,80) Furthermore, species-specific traits of animals’ behavior are linked to peculiarities of b…”
BackgroundHoh Kam, J., Lenassi, E., & Jeffery, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013127 · Cited by 131 · cited 4×
“The presence of these cells may be indicative of an attempt to clear Aβ, but it has also been suggested that they may be accomplices in the development of AMD.98 Recently, we showed that Aβ 1–42 accumulates with age in the OXYS retina, but its level is not elevated at the early stages of retinopathy (age 3 mo, Fig.”
BackgroundInfluentialDistribution and Expression of Picalm in Alzheimer Disease
Baig, S., Joseph, S. A., Tayler, H., Abraham, R., Owen, M. J., Williams, J., Kehoe, P. G., & Love, S. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181f52e01 · Cited by 115 · cited 1×
“Thus, both overexpression and underexpression of PICALM disrupt the processes of endocytosis, which plays an important role in the nervous system.(100) Recent genome-wide association studies (GWAS) have found that PICALM mutations are significantly associated with AD, suggesting that PICALM has a hand in AβPP endocyto…”
BackgroundObukhova, L. A., Skulachev, V. P., & Kolosova, N. G. (2009) · Aging · doi:10.18632/aging.100043 · Cited by 106
Self-citationBeneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease
Jaszberenyi, M., Rick, F. G., Szalontay, L., Block, N. L., Zarandi, M., Cai, R.-Z., & Schally, A. V. (2012) · Aging · doi:10.18632/aging.100504 · Cited by 48
Capetillo-Zarate, E., Staufenbiel, M., Abramowski, D., Haass, C., Escher, A., Stadelmann, C., Yamaguchi, H., Wiestler, O. D., & Thal, D. R. (2006) · Brain · doi:10.1093/brain/awl176 · Cited by 45
Cited by
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870
Senescence in the pathogenesis of age-related macular degeneration
Blasiak, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03420-x · Cited by 183
“Senescence-accelerated OXYS rats are a model of accelerated aging and several neurodegenerative diseases, including AMD [61].”
BackgroundEmerging insights in senescence: pathways from preclinical models to therapeutic innovations
Mansfield, L., Ramponi, V., Gupta, K., Stevenson, T., Mathew, A. B., Barinda, A. J., Herbstein, F., & Morsli, S. (2024) · npj Aging · doi:10.1038/s41514-024-00181-1 · Cited by 88
Muraleva, N. A., Stefanova, N. A., & Kolosova, N. G. (2020) · Antioxidants · doi:10.3390/antiox9080676 · Cited by 40
“Similar results about the treatment and prevention of AD-like pathology by SkQ1 have been obtained in several other studies on SkQ1’s effects on the dynamics of neurodegenerative changes in OXYS rats [11,13,15].”
BackgroundResultSelf-citationStefanova, N. A., Ershov, N. I., & Kolosova, N. G. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3984906 · Cited by 40
Self-citation
Metadata
- Authors
- Stefanova, N., Kozhevnikova, O., Vitovtov, A., Maksimova, K., Logvinov, S., Rudnitskaya, E., Korbolina, E., Muraleva, N., & Kolosova, N.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2014-02-17
- Volume
- 13
- Issue
- 6
- Pages
- 898-909
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2003627315
- Cited by
- 96
- References
- 28
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.